Safety and activity of alectinib plus bevacizumab in patients with advanced ALK-rearranged non-small-cell lung cancer: a phase I/II study

por Lin, J.J., Muzikansky, A., Kennedy, E., Kuberski, H., Stober, L.L., Wanat, A.C., Azzoli, C.G., Lennes, I., Sequist, L.V., Dagogo-Jack, I., Shaw, A.T., Gainor, J.F.
Publicado 2021